Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-Effect Study of Hemay022 in Healthy Subjects
NCT04673474Phase 1Unknown
- Sponsor
- Tianjin Hemay Oncology Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacibertinib in HER2-positive breast cancer (2 arms), sponsored by Tianjin Hemay Oncology Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Plasma Concentration at Day 8 and 2 more. Status: unknown.
02
Drugs
sacibertinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04673474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673474.